Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|December 11, 2017
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinomaMaeve A Lowery, David P Kelsen, Marinela Capanu, et al.
Annals of Surgery|June 6, 2014
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinomaEileen M OʼReilly, Anna Perelshteyn, William R Jarnagin, et al.
Journal of the National Cancer Institute|March 23, 2021
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and OutcomesAnna M Varghese, Isha Singh, Rituraj Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for InterventionMaeve A Lowery, Ryan Ptashkin, Emmet Jordan, et al.
Cancer|January 17, 2018
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinomaEileen M O'Reilly, Jonathan W Lee, Maeve A Lowery, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
The Lancet. Oncology|October 24, 2023
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Do-Youn Oh, Patricio Yañez, et al.
The Lancet. Gastroenterology & Hepatology|September 21, 2023
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trialJohn V Reynolds, Shaun R Preston, Brian O'Neill, et al.
The Lancet. Oncology|May 17, 2020
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyGhassan K Abou-Alfa, Teresa Macarulla, Milind M Javle, et al.
Acta Oncologica (Stockholm, Sweden)|May 23, 2024
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in EuropeKjetil Taskén, Soemeya F Haj Mohammad, Gro Live Fagereng, et al.
Pageof 7